600 related articles for article (PubMed ID: 9776134)
21. MK801 influences L-DOPA-induced dopamine release in intact and hemi-parkinson rats.
Jonkers N; Sarre S; Ebinger G; Michotte Y
Eur J Pharmacol; 2000 Nov; 407(3):281-91. PubMed ID: 11068024
[TBL] [Abstract][Full Text] [Related]
22. Dopamine receptors: effects of chronic L-dopa and bromocriptine treatment in an animal model of Parkinson's disease.
Schneider MB; Murrin LC; Pfeiffer RF; Deupree JD
Clin Neuropharmacol; 1984; 7(3):247-57. PubMed ID: 6435870
[TBL] [Abstract][Full Text] [Related]
23. Subchronic administration of L-DOPA to adult rats with a unilateral 6-hydroxydopamine lesion of dopamine neurons results in a sensitization of enhanced GABA release in the substantia nigra, pars reticulata.
Yamamoto N; Pierce RC; Soghomonian JJ
Brain Res; 2006 Dec; 1123(1):196-200. PubMed ID: 17027936
[TBL] [Abstract][Full Text] [Related]
24. Serotonergic activation after 2-week intrastriatal infusion of L-dopa and slow recovery of circling in rats with unilateral nigral lesions.
Kääriäinen TM; García-Horsman JA; Piltonen M; Huotari M; Männistö PT
Basic Clin Pharmacol Toxicol; 2008 Mar; 102(3):300-7. PubMed ID: 17973898
[TBL] [Abstract][Full Text] [Related]
25. Synergistic effect of SCH 58261, an adenosine A2A receptor antagonist, and L-DOPA on the reserpine-induced muscle rigidity in rats.
Wardas J
Pol J Pharmacol; 2003; 55(2):155-64. PubMed ID: 12926542
[TBL] [Abstract][Full Text] [Related]
26. Induction of dopamine biosynthesis by l-DOPA in PC12 cells: implications of L-DOPA influx and cyclic AMP.
Jin CM; Yang YJ; Huang HS; Lim SC; Kai M; Lee MK
Eur J Pharmacol; 2008 Sep; 591(1-3):88-95. PubMed ID: 18602388
[TBL] [Abstract][Full Text] [Related]
27. Dopamine synthesis by non-dopaminergic neurons expressing individual complementary enzymes of the dopamine synthetic pathway in the arcuate nucleus of fetal rats.
Ugrumov MV; Melnikova VI; Lavrentyeva AV; Kudrin VS; Rayevsky KS
Neuroscience; 2004; 124(3):629-35. PubMed ID: 14980733
[TBL] [Abstract][Full Text] [Related]
28. Pentobarbital inhibits L-DOPA-induced dopamine increases in the rat striatum: An in vivo microdialysis study.
Adachi YU; Yamada S; Satomoto M; Watanabe K; Higuchi H; Kazama T; Doi M; Sato S
Brain Res Bull; 2006 May; 69(5):593-6. PubMed ID: 16647588
[TBL] [Abstract][Full Text] [Related]
29. NMDA receptor antagonism potentiates the L-DOPA-induced extracellular dopamine release in the subthalamic nucleus of hemi-parkinson rats.
El Arfani A; Bentea E; Aourz N; Ampe B; De Deurwaerdère P; Van Eeckhaut A; Massie A; Sarre S; Smolders I; Michotte Y
Neuropharmacology; 2014 Oct; 85():198-205. PubMed ID: 24863042
[TBL] [Abstract][Full Text] [Related]
30. Biotransformation of L-DOPA to dopamine in the substantia nigra of freely moving rats: effect of dopamine receptor agonists and antagonists.
Sarre S; Vandeneede D; Ebinger G; Michotte Y
J Neurochem; 1998 Apr; 70(4):1730-9. PubMed ID: 9523592
[TBL] [Abstract][Full Text] [Related]
31. Muscarinic antagonists in substantia nigra influence the decarboxylation of L-dopa in striatum.
Izurieta-Sánchez P; Sarre S; Ebinger G; Michotte Y
Eur J Pharmacol; 2000 Jul; 399(2-3):151-60. PubMed ID: 10884514
[TBL] [Abstract][Full Text] [Related]
32. l-dopa-induced reversal in striatal glutamate following partial depletion of nigrostriatal dopamine with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Holmer HK; Keyghobadi M; Moore C; Meshul CK
Neuroscience; 2005; 136(1):333-41. PubMed ID: 16198485
[TBL] [Abstract][Full Text] [Related]
33. Tetrahydrobiopterin stimulates L-DOPA release from striatal tissue.
Abreu-González P; González-Hernández T; Afonso-Oramas D; Cruz-Muros I; Barroso-Chinea P; González MC
Eur J Pharmacol; 2006 Jul; 541(1-2):33-7. PubMed ID: 16750826
[TBL] [Abstract][Full Text] [Related]
34. Blockade of A2A receptors plus l-DOPA after nigrostriatal lesion results in GAD67 mRNA changes different from l-DOPA alone in the rat globus pallidus and substantia nigra reticulata.
Carta AR; Tabrizi MA; Baraldi PG; Pinna A; Pala P; Morelli M
Exp Neurol; 2003 Dec; 184(2):679-87. PubMed ID: 14769359
[TBL] [Abstract][Full Text] [Related]
35. The L-amino acid carrier inhibitor 2-aminobicyclo[2.2.1]heptane-2-carboxylic acid (BCH) reduces L-dopa-elicited responses in dopaminergic neurons of the substantia nigra pars compacta.
Sebastianelli L; Ledonne A; Marrone MC; Bernardi G; Mercuri NB
Exp Neurol; 2008 Jul; 212(1):230-3. PubMed ID: 18501350
[TBL] [Abstract][Full Text] [Related]
36. L-DOPA modulation of corpus striatal dopamine and dihydroxyphenylacetic acid output from intact and 6-OHDA lesioned rats.
Xu K; Dluzen DE
J Neural Transm (Vienna); 1996; 103(11):1295-305. PubMed ID: 9013416
[TBL] [Abstract][Full Text] [Related]
37. 6-OHDA-induced hemiparkinsonism and chronic L-DOPA treatment increase dopamine D1-stimulated [(3)H]-GABA release and [(3)H]-cAMP production in substantia nigra pars reticulata of the rat.
Rangel-Barajas C; Silva I; García-Ramírez M; Sánchez-Lemus E; Floran L; Aceves J; Erlij D; Florán B
Neuropharmacology; 2008 Oct; 55(5):704-11. PubMed ID: 18588904
[TBL] [Abstract][Full Text] [Related]
38. Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease.
Mela F; Marti M; Dekundy A; Danysz W; Morari M; Cenci MA
J Neurochem; 2007 Apr; 101(2):483-97. PubMed ID: 17359492
[TBL] [Abstract][Full Text] [Related]
39. Zonisamide enhances delta receptor-associated neurotransmitter release in striato-pallidal pathway.
Yamamura S; Ohoyama K; Nagase H; Okada M
Neuropharmacology; 2009 Sep; 57(3):322-31. PubMed ID: 19482038
[TBL] [Abstract][Full Text] [Related]
40. Actions at sites other than D(3) receptors mediate the effects of BP897 on l-DOPA-induced hyperactivity in monoamine-depleted rats.
Visanji NP; Millan MJ; Brotchie JM
Exp Neurol; 2006 Nov; 202(1):85-92. PubMed ID: 16814282
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
